The FDA Type B meeting and UK MAA submission for AMT-130 are the key near-term catalysts. Watch for details on the proposed Phase III trial design and the four-year AMT-130 data analysis expected in Q3 2026, which will determine the regulatory path forward in the US.
Drugs in focus
QURE drug pipeline →AMT-130
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 1/2 (pivotal for accelerated approval)
- Time to market
- BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
- Next catalyst
- None dated
What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
Price Chart
Executive Summary
Key pipeline updates include a scheduled Type B meeting with the FDA for AMT-130 in Huntington's disease and an expected UK MAA submission in Q3 2026, offset by the discontinuation of the AMT-162 ALS program. Cash and investments stood at $586.6M, with runway into H2 2029.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $3.6M vs $1.6M in Q1 2025, driven by higher license revenue.
- Cash, cash equivalents and current investment securities of $586.6M as of March 31, 2026, down from $622.5M at year-end 2025.
- Type B meeting with FDA granted to discuss potential new clinical trial design for AMT-130; MAA submission to UK MHRA expected in Q3 2026.
- AMT-162 (SOD1-ALS) development discontinued after review of preliminary safety and efficacy data.
- HEMGENIX supply agreements restructured: uniQure's remaining supply commitments to terminate in mid-2026; no impact on future royalties.
- All 11 dosed patients in AMT-191 Fabry disease study have discontinued enzyme replacement therapy.
Financial Impact
Revenue $3.6M, net loss $53.5M, cash burn $35.9M from Dec 2025 to Mar 2026.
Risk Factors
- FDA has stated Phase I/II data with external control are insufficient for a BLA; a new randomized sham-controlled study may be required, adding years and cost.
- Cash burn rate implies ~$144M annual operating cash outflow; runway into H2 2029 depends on no major new spending commitments.
- AMT-162 discontinuation removes a pipeline asset; AMT-260 and AMT-191 remain early-stage with clinical holds on certain cohorts.
- Royalty financing liability of $482M and long-term debt of $50M add balance sheet leverage.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-055242 |
| Document: qure-20260505x8k.htm | 0001104659-26-055242 |
| Document: 0001104659-26-055242-index-headers.html | 0001104659-26-055242 |
| Document: 0001104659-26-055242-index.html | 0001104659-26-055242 |
| Document: 0001104659-26-055242.txt | 0001104659-26-055242 |
| 8-K Data (Synthetic) | 0001104659-26-055242 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers